nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—Cytochrome P450 3A4 Inducers—Amprenavir—acquired immunodeficiency syndrome	0.254	0.439	CiPCiCtD
Aprepitant—Cytochrome P450 3A4 Inhibitors—Amprenavir—acquired immunodeficiency syndrome	0.134	0.232	CiPCiCtD
Aprepitant—Cytochrome P450 3A4 Inhibitors—Efavirenz—acquired immunodeficiency syndrome	0.0957	0.165	CiPCiCtD
Aprepitant—Cytochrome P450 3A4 Inhibitors—Ritonavir—acquired immunodeficiency syndrome	0.0957	0.165	CiPCiCtD
Aprepitant—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0105	0.0346	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0105	0.0346	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.00904	0.0299	CbGbCtD
Aprepitant—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.00904	0.0299	CbGbCtD
Aprepitant—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.00877	0.029	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.00877	0.029	CbGbCtD
Aprepitant—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.00869	0.0287	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.00794	0.0262	CbGbCtD
Aprepitant—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.00794	0.0262	CbGbCtD
Aprepitant—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.00794	0.0262	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.00794	0.0262	CbGbCtD
Aprepitant—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.00785	0.0259	CbGbCtD
Aprepitant—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.00785	0.0259	CbGbCtD
Aprepitant—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.00745	0.0246	CbGbCtD
Aprepitant—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.00701	0.0231	CbGbCtD
Aprepitant—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.00688	0.0227	CbGbCtD
Aprepitant—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.00678	0.0224	CbGbCtD
Aprepitant—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.00658	0.0217	CbGbCtD
Aprepitant—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.00646	0.0213	CbGbCtD
Aprepitant—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.00646	0.0213	CbGbCtD
Aprepitant—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.00634	0.0209	CbGbCtD
Aprepitant—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.00634	0.0209	CbGbCtD
Aprepitant—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0062	0.0205	CbGbCtD
Aprepitant—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.00595	0.0197	CbGbCtD
Aprepitant—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.00595	0.0197	CbGbCtD
Aprepitant—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.00585	0.0193	CbGbCtD
Aprepitant—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.00582	0.0192	CbGbCtD
Aprepitant—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.00582	0.0192	CbGbCtD
Aprepitant—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.00547	0.0181	CbGbCtD
Aprepitant—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.00531	0.0175	CbGbCtD
Aprepitant—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.00527	0.0174	CbGbCtD
Aprepitant—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.00527	0.0174	CbGbCtD
Aprepitant—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0049	0.0162	CbGbCtD
Aprepitant—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0048	0.0159	CbGbCtD
Aprepitant—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0048	0.0159	CbGbCtD
Aprepitant—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0046	0.0152	CbGbCtD
Aprepitant—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00455	0.015	CbGbCtD
Aprepitant—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00443	0.0146	CbGbCtD
Aprepitant—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00441	0.0146	CbGbCtD
Aprepitant—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00399	0.0132	CbGbCtD
Aprepitant—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00399	0.0132	CbGbCtD
Aprepitant—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00383	0.0126	CbGbCtD
Aprepitant—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0036	0.0119	CbGbCtD
Aprepitant—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00339	0.0112	CbGbCtD
Aprepitant—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00339	0.0112	CbGbCtD
Aprepitant—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00306	0.0101	CbGbCtD
Aprepitant—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00306	0.0101	CbGbCtD
Aprepitant—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00264	0.00873	CbGbCtD
Aprepitant—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00257	0.00848	CbGbCtD
Aprepitant—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00232	0.00767	CbGbCtD
Aprepitant—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00232	0.00767	CbGbCtD
Aprepitant—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00223	0.00735	CbGbCtD
Aprepitant—TACR1—nerve—acquired immunodeficiency syndrome	0.00188	0.146	CbGeAlD
Aprepitant—TACR3—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00118	0.0568	CbGpPWpGaD
Aprepitant—TACR3—nervous system—acquired immunodeficiency syndrome	0.00109	0.0845	CbGeAlD
Aprepitant—TACR3—central nervous system—acquired immunodeficiency syndrome	0.00105	0.0814	CbGeAlD
Aprepitant—TACR3—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000919	0.0441	CbGpPWpGaD
Aprepitant—TACR3—brain—acquired immunodeficiency syndrome	0.000834	0.0646	CbGeAlD
Aprepitant—TACR3—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000662	0.0318	CbGpPWpGaD
Aprepitant—TACR3—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000622	0.0299	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000617	0.0296	CbGpPWpGaD
Aprepitant—TACR1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000578	0.0278	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000557	0.0267	CbGpPWpGaD
Aprepitant—TACR1—digestive system—acquired immunodeficiency syndrome	0.000546	0.0423	CbGeAlD
Aprepitant—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000543	0.042	CbGeAlD
Aprepitant—TACR1—blood—acquired immunodeficiency syndrome	0.000521	0.0403	CbGeAlD
Aprepitant—TACR3—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000504	0.0242	CbGpPWpGaD
Aprepitant—TACR1—spinal cord—acquired immunodeficiency syndrome	0.000502	0.0388	CbGeAlD
Aprepitant—TACR3—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00047	0.0225	CbGpPWpGaD
Aprepitant—TACR1—lung—acquired immunodeficiency syndrome	0.000456	0.0353	CbGeAlD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000449	0.0215	CbGpPWpGaD
Aprepitant—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000443	0.0343	CbGeAlD
Aprepitant—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000428	0.0331	CbGeAlD
Aprepitant—TACR3—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000426	0.0205	CbGpPWpGaD
Aprepitant—TACR1—nervous system—acquired immunodeficiency syndrome	0.000423	0.0327	CbGeAlD
Aprepitant—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000421	0.0326	CbGeAlD
Aprepitant—TACR1—central nervous system—acquired immunodeficiency syndrome	0.000407	0.0315	CbGeAlD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000374	0.0179	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000344	0.0165	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000338	0.0162	CbGpPWpGaD
Aprepitant—TACR1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000323	0.0155	CbGpPWpGaD
Aprepitant—TACR1—brain—acquired immunodeficiency syndrome	0.000323	0.025	CbGeAlD
Aprepitant—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000321	0.0248	CbGeAlD
Aprepitant—TACR1—lymph node—acquired immunodeficiency syndrome	0.000312	0.0242	CbGeAlD
Aprepitant—TACR3—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000311	0.0149	CbGpPWpGaD
Aprepitant—TACR1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000304	0.0146	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000301	0.0145	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000293	0.014	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000293	0.014	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000284	0.0137	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000272	0.0131	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000257	0.0123	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000246	0.0118	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000241	0.0116	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000231	0.0111	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000229	0.011	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000223	0.0107	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.000222	0.0107	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000209	0.01	CbGpPWpGaD
Aprepitant—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000209	0.0162	CbGeAlD
Aprepitant—TACR1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000208	0.00999	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000201	0.00962	CbGpPWpGaD
Aprepitant—CYP2C19—blood—acquired immunodeficiency syndrome	0.000199	0.0154	CbGeAlD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000196	0.00942	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000196	0.00942	CbGpPWpGaD
Aprepitant—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000184	0.0143	CbGeAlD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000182	0.00875	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000176	0.00843	CbGpPWpGaD
Aprepitant—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.00017	0.0132	CbGeAlD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000168	0.00806	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000165	0.00792	CbGpPWpGaD
Aprepitant—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000164	0.0127	CbGeAlD
Aprepitant—CYP1A2—blood—acquired immunodeficiency syndrome	0.000162	0.0126	CbGeAlD
Aprepitant—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000162	0.0125	CbGeAlD
Aprepitant—TACR3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000159	0.00763	CbGpPWpGaD
Aprepitant—CYP3A5—blood—acquired immunodeficiency syndrome	0.000157	0.0121	CbGeAlD
Aprepitant—TACR1—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	0.000154	0.0074	CbGpPWpGaD
Aprepitant—CYP2C9—blood—acquired immunodeficiency syndrome	0.000154	0.0119	CbGeAlD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000152	0.00729	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000149	0.00717	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000149	0.00717	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000149	0.00716	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000146	0.00701	CbGpPWpGaD
Aprepitant—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000145	0.0112	CbGeAlD
Aprepitant—TACR1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000143	0.00686	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000143	0.00686	CbGpPWpGaD
Aprepitant—CYP1A2—lung—acquired immunodeficiency syndrome	0.000142	0.011	CbGeAlD
Aprepitant—TACR3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000142	0.00683	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000139	0.00667	CbGpPWpGaD
Aprepitant—CYP3A5—lung—acquired immunodeficiency syndrome	0.000137	0.0106	CbGeAlD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000134	0.00645	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000132	0.00634	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000127	0.00608	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000126	0.00603	CbGpPWpGaD
Aprepitant—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000123	0.00955	CbGeAlD
Aprepitant—TACR1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000118	0.00565	CbGpPWpGaD
Aprepitant—CYP3A4—blood—acquired immunodeficiency syndrome	0.000118	0.0091	CbGeAlD
Aprepitant—TACR3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000114	0.00546	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000113	0.00541	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000109	0.00522	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000102	0.00491	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000102	0.00489	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	9.79e-05	0.0047	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	9.58e-05	0.0046	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	9.58e-05	0.0046	CbGpPWpGaD
Aprepitant—CYP3A4—nervous system—acquired immunodeficiency syndrome	9.54e-05	0.00739	CbGeAlD
Aprepitant—TACR1—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	9.32e-05	0.00447	CbGpPWpGaD
Aprepitant—CYP3A4—central nervous system—acquired immunodeficiency syndrome	9.19e-05	0.00711	CbGeAlD
Aprepitant—TACR3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.02e-05	0.00433	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.98e-05	0.00431	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.62e-05	0.00414	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.62e-05	0.00414	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	8.58e-05	0.00412	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.44e-05	0.00405	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.44e-05	0.00405	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	8.28e-05	0.00397	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.16e-05	0.00391	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.8e-05	0.00374	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.76e-05	0.00372	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.67e-05	0.00368	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.67e-05	0.00368	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.3e-05	0.0035	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.3e-05	0.0035	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.29e-05	0.0035	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.13e-05	0.00342	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.95e-05	0.00334	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.57e-05	0.00315	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.45e-05	0.00309	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.42e-05	0.00308	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.33e-05	0.00304	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.17e-05	0.00296	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	6.03e-05	0.00289	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.83e-05	0.0028	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.79e-05	0.00278	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.75e-05	0.00276	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.55e-05	0.00266	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.33e-05	0.00256	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.26e-05	0.00252	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5e-05	0.0024	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	4.87e-05	0.00234	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	4.82e-05	0.00232	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.82e-05	0.00231	CbGpPWpGaD
Aprepitant—Anxiety—Ritonavir—acquired immunodeficiency syndrome	4.62e-05	0.000554	CcSEcCtD
Aprepitant—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	4.61e-05	0.000552	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	4.61e-05	0.000552	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	4.59e-05	0.00055	CcSEcCtD
Aprepitant—Pruritus—Abacavir—acquired immunodeficiency syndrome	4.59e-05	0.000549	CcSEcCtD
Aprepitant—Fatigue—Indinavir—acquired immunodeficiency syndrome	4.59e-05	0.000549	CcSEcCtD
Aprepitant—Anorexia—Delavirdine—acquired immunodeficiency syndrome	4.58e-05	0.000549	CcSEcCtD
Aprepitant—Discomfort—Ritonavir—acquired immunodeficiency syndrome	4.58e-05	0.000549	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	4.58e-05	0.000549	CcSEcCtD
Aprepitant—Cough—Saquinavir—acquired immunodeficiency syndrome	4.58e-05	0.000548	CcSEcCtD
Aprepitant—Angioedema—Lamivudine—acquired immunodeficiency syndrome	4.57e-05	0.000548	CcSEcCtD
Aprepitant—Pain—Indinavir—acquired immunodeficiency syndrome	4.55e-05	0.000545	CcSEcCtD
Aprepitant—Constipation—Indinavir—acquired immunodeficiency syndrome	4.55e-05	0.000545	CcSEcCtD
Aprepitant—Insomnia—Efavirenz—acquired immunodeficiency syndrome	4.55e-05	0.000545	CcSEcCtD
Aprepitant—Urticaria—Zidovudine—acquired immunodeficiency syndrome	4.54e-05	0.000544	CcSEcCtD
Aprepitant—Convulsion—Saquinavir—acquired immunodeficiency syndrome	4.54e-05	0.000544	CcSEcCtD
Aprepitant—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	4.54e-05	0.000543	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.53e-05	0.00217	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.53e-05	0.00217	CbGpPWpGaD
Aprepitant—Hypertension—Saquinavir—acquired immunodeficiency syndrome	4.53e-05	0.000542	CcSEcCtD
Aprepitant—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	4.52e-05	0.000542	CcSEcCtD
Aprepitant—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	4.52e-05	0.000542	CcSEcCtD
Aprepitant—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	4.52e-05	0.000541	CcSEcCtD
Aprepitant—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	4.51e-05	0.000541	CcSEcCtD
Aprepitant—Malaise—Lamivudine—acquired immunodeficiency syndrome	4.51e-05	0.00054	CcSEcCtD
Aprepitant—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	4.5e-05	0.000539	CcSEcCtD
Aprepitant—Nausea—Didanosine—acquired immunodeficiency syndrome	4.5e-05	0.000539	CcSEcCtD
Aprepitant—Hypotension—Delavirdine—acquired immunodeficiency syndrome	4.49e-05	0.000538	CcSEcCtD
Aprepitant—Syncope—Lamivudine—acquired immunodeficiency syndrome	4.49e-05	0.000537	CcSEcCtD
Aprepitant—Confusional state—Ritonavir—acquired immunodeficiency syndrome	4.48e-05	0.000537	CcSEcCtD
Aprepitant—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	4.48e-05	0.000537	CcSEcCtD
Aprepitant—Somnolence—Efavirenz—acquired immunodeficiency syndrome	4.47e-05	0.000535	CcSEcCtD
Aprepitant—Myalgia—Saquinavir—acquired immunodeficiency syndrome	4.46e-05	0.000535	CcSEcCtD
Aprepitant—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	4.46e-05	0.000535	CcSEcCtD
Aprepitant—Chest pain—Saquinavir—acquired immunodeficiency syndrome	4.46e-05	0.000535	CcSEcCtD
Aprepitant—Anxiety—Saquinavir—acquired immunodeficiency syndrome	4.45e-05	0.000533	CcSEcCtD
Aprepitant—Oedema—Ritonavir—acquired immunodeficiency syndrome	4.45e-05	0.000533	CcSEcCtD
Aprepitant—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	4.43e-05	0.000531	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	4.43e-05	0.000531	CcSEcCtD
Aprepitant—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	4.42e-05	0.00053	CcSEcCtD
Aprepitant—Discomfort—Saquinavir—acquired immunodeficiency syndrome	4.41e-05	0.000528	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.4e-05	0.00211	CbGpPWpGaD
Aprepitant—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	4.4e-05	0.000527	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.39e-05	0.0021	CbGpPWpGaD
Aprepitant—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	4.38e-05	0.000525	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	4.38e-05	0.000525	CcSEcCtD
Aprepitant—Shock—Ritonavir—acquired immunodeficiency syndrome	4.37e-05	0.000524	CcSEcCtD
Aprepitant—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	4.37e-05	0.000523	CcSEcCtD
Aprepitant—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	4.37e-05	0.000523	CcSEcCtD
Aprepitant—Cough—Lamivudine—acquired immunodeficiency syndrome	4.37e-05	0.000523	CcSEcCtD
Aprepitant—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	4.36e-05	0.000523	CcSEcCtD
Aprepitant—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	4.36e-05	0.000522	CcSEcCtD
Aprepitant—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	4.35e-05	0.000522	CcSEcCtD
Aprepitant—Dizziness—Stavudine—acquired immunodeficiency syndrome	4.35e-05	0.000521	CcSEcCtD
Aprepitant—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	4.35e-05	0.000521	CcSEcCtD
Aprepitant—Insomnia—Delavirdine—acquired immunodeficiency syndrome	4.35e-05	0.000521	CcSEcCtD
Aprepitant—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	4.34e-05	0.00052	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	4.34e-05	0.00052	CcSEcCtD
Aprepitant—Convulsion—Lamivudine—acquired immunodeficiency syndrome	4.33e-05	0.000519	CcSEcCtD
Aprepitant—Vomiting—Nevirapine—acquired immunodeficiency syndrome	4.33e-05	0.000519	CcSEcCtD
Aprepitant—Fatigue—Efavirenz—acquired immunodeficiency syndrome	4.33e-05	0.000519	CcSEcCtD
Aprepitant—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	4.32e-05	0.000517	CcSEcCtD
Aprepitant—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	4.32e-05	0.000517	CcSEcCtD
Aprepitant—Confusional state—Saquinavir—acquired immunodeficiency syndrome	4.31e-05	0.000517	CcSEcCtD
Aprepitant—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	4.3e-05	0.000515	CcSEcCtD
Aprepitant—Constipation—Efavirenz—acquired immunodeficiency syndrome	4.3e-05	0.000515	CcSEcCtD
Aprepitant—Pain—Efavirenz—acquired immunodeficiency syndrome	4.3e-05	0.000515	CcSEcCtD
Aprepitant—Rash—Nevirapine—acquired immunodeficiency syndrome	4.3e-05	0.000515	CcSEcCtD
Aprepitant—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	4.29e-05	0.000514	CcSEcCtD
Aprepitant—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	4.29e-05	0.000514	CcSEcCtD
Aprepitant—Dizziness—Abacavir—acquired immunodeficiency syndrome	4.29e-05	0.000514	CcSEcCtD
Aprepitant—Oedema—Saquinavir—acquired immunodeficiency syndrome	4.28e-05	0.000513	CcSEcCtD
Aprepitant—Somnolence—Delavirdine—acquired immunodeficiency syndrome	4.27e-05	0.000512	CcSEcCtD
Aprepitant—Headache—Nevirapine—acquired immunodeficiency syndrome	4.27e-05	0.000512	CcSEcCtD
Aprepitant—Myalgia—Lamivudine—acquired immunodeficiency syndrome	4.26e-05	0.00051	CcSEcCtD
Aprepitant—Chest pain—Lamivudine—acquired immunodeficiency syndrome	4.26e-05	0.00051	CcSEcCtD
Aprepitant—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	4.26e-05	0.00051	CcSEcCtD
Aprepitant—Infection—Saquinavir—acquired immunodeficiency syndrome	4.25e-05	0.000509	CcSEcCtD
Aprepitant—Anxiety—Lamivudine—acquired immunodeficiency syndrome	4.24e-05	0.000508	CcSEcCtD
Aprepitant—Anorexia—Ritonavir—acquired immunodeficiency syndrome	4.24e-05	0.000508	CcSEcCtD
Aprepitant—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	4.23e-05	0.000507	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	4.23e-05	0.000507	CcSEcCtD
Aprepitant—Urticaria—Indinavir—acquired immunodeficiency syndrome	4.23e-05	0.000506	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.21e-05	0.00202	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.21e-05	0.00202	CbGpPWpGaD
Aprepitant—Shock—Saquinavir—acquired immunodeficiency syndrome	4.21e-05	0.000504	CcSEcCtD
Aprepitant—Discomfort—Lamivudine—acquired immunodeficiency syndrome	4.21e-05	0.000504	CcSEcCtD
Aprepitant—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	4.2e-05	0.000504	CcSEcCtD
Aprepitant—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	4.2e-05	0.000504	CcSEcCtD
Aprepitant—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	4.2e-05	0.000503	CcSEcCtD
Aprepitant—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	4.2e-05	0.000503	CcSEcCtD
Aprepitant—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	4.19e-05	0.000502	CcSEcCtD
Aprepitant—Vomiting—Stavudine—acquired immunodeficiency syndrome	4.18e-05	0.000501	CcSEcCtD
Aprepitant—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	4.18e-05	0.000501	CcSEcCtD
Aprepitant—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	4.16e-05	0.000499	CcSEcCtD
Aprepitant—Rash—Nelfinavir—acquired immunodeficiency syndrome	4.16e-05	0.000499	CcSEcCtD
Aprepitant—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	4.16e-05	0.000498	CcSEcCtD
Aprepitant—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	4.16e-05	0.000498	CcSEcCtD
Aprepitant—Hypotension—Ritonavir—acquired immunodeficiency syndrome	4.15e-05	0.000498	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	4.15e-05	0.000497	CcSEcCtD
Aprepitant—Rash—Stavudine—acquired immunodeficiency syndrome	4.15e-05	0.000497	CcSEcCtD
Aprepitant—Fatigue—Delavirdine—acquired immunodeficiency syndrome	4.15e-05	0.000497	CcSEcCtD
Aprepitant—Dermatitis—Stavudine—acquired immunodeficiency syndrome	4.14e-05	0.000497	CcSEcCtD
Aprepitant—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	4.14e-05	0.000496	CcSEcCtD
Aprepitant—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	4.14e-05	0.000496	CcSEcCtD
Aprepitant—Headache—Nelfinavir—acquired immunodeficiency syndrome	4.13e-05	0.000495	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.12e-05	0.00198	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.12e-05	0.00198	CbGpPWpGaD
Aprepitant—Headache—Stavudine—acquired immunodeficiency syndrome	4.12e-05	0.000494	CcSEcCtD
Aprepitant—Vomiting—Abacavir—acquired immunodeficiency syndrome	4.12e-05	0.000494	CcSEcCtD
Aprepitant—Confusional state—Lamivudine—acquired immunodeficiency syndrome	4.12e-05	0.000493	CcSEcCtD
Aprepitant—Pain—Delavirdine—acquired immunodeficiency syndrome	4.11e-05	0.000493	CcSEcCtD
Aprepitant—Constipation—Delavirdine—acquired immunodeficiency syndrome	4.11e-05	0.000493	CcSEcCtD
Aprepitant—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	4.11e-05	0.000492	CcSEcCtD
Aprepitant—Asthenia—Zidovudine—acquired immunodeficiency syndrome	4.1e-05	0.000492	CcSEcCtD
Aprepitant—Rash—Abacavir—acquired immunodeficiency syndrome	4.09e-05	0.00049	CcSEcCtD
Aprepitant—Dermatitis—Abacavir—acquired immunodeficiency syndrome	4.08e-05	0.000489	CcSEcCtD
Aprepitant—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	4.08e-05	0.000489	CcSEcCtD
Aprepitant—Oedema—Lamivudine—acquired immunodeficiency syndrome	4.08e-05	0.000489	CcSEcCtD
Aprepitant—Anorexia—Saquinavir—acquired immunodeficiency syndrome	4.08e-05	0.000489	CcSEcCtD
Aprepitant—Headache—Abacavir—acquired immunodeficiency syndrome	4.06e-05	0.000487	CcSEcCtD
Aprepitant—Infection—Lamivudine—acquired immunodeficiency syndrome	4.06e-05	0.000486	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	4.05e-05	0.000485	CcSEcCtD
Aprepitant—Nausea—Nevirapine—acquired immunodeficiency syndrome	4.05e-05	0.000485	CcSEcCtD
Aprepitant—Pruritus—Zidovudine—acquired immunodeficiency syndrome	4.05e-05	0.000485	CcSEcCtD
Aprepitant—Insomnia—Ritonavir—acquired immunodeficiency syndrome	4.02e-05	0.000482	CcSEcCtD
Aprepitant—Shock—Lamivudine—acquired immunodeficiency syndrome	4.02e-05	0.000481	CcSEcCtD
Aprepitant—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	4e-05	0.00048	CcSEcCtD
Aprepitant—Hypotension—Saquinavir—acquired immunodeficiency syndrome	4e-05	0.000479	CcSEcCtD
Aprepitant—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	4e-05	0.000479	CcSEcCtD
Aprepitant—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	3.99e-05	0.000478	CcSEcCtD
Aprepitant—Urticaria—Efavirenz—acquired immunodeficiency syndrome	3.99e-05	0.000478	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.98e-05	0.00191	CbGpPWpGaD
Aprepitant—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	3.97e-05	0.000476	CcSEcCtD
Aprepitant—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	3.97e-05	0.000476	CcSEcCtD
Aprepitant—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	3.97e-05	0.000475	CcSEcCtD
Aprepitant—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	3.96e-05	0.000475	CcSEcCtD
Aprepitant—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	3.96e-05	0.000475	CcSEcCtD
Aprepitant—Somnolence—Ritonavir—acquired immunodeficiency syndrome	3.95e-05	0.000474	CcSEcCtD
Aprepitant—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	3.95e-05	0.000473	CcSEcCtD
Aprepitant—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	3.93e-05	0.000471	CcSEcCtD
Aprepitant—Nausea—Nelfinavir—acquired immunodeficiency syndrome	3.92e-05	0.00047	CcSEcCtD
Aprepitant—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	3.92e-05	0.000469	CcSEcCtD
Aprepitant—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	3.91e-05	0.000469	CcSEcCtD
Aprepitant—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	3.91e-05	0.000469	CcSEcCtD
Aprepitant—Nausea—Stavudine—acquired immunodeficiency syndrome	3.91e-05	0.000468	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	3.9e-05	0.000467	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.89e-05	0.00187	CbGpPWpGaD
Aprepitant—Anorexia—Lamivudine—acquired immunodeficiency syndrome	3.89e-05	0.000466	CcSEcCtD
Aprepitant—Insomnia—Saquinavir—acquired immunodeficiency syndrome	3.87e-05	0.000464	CcSEcCtD
Aprepitant—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	3.87e-05	0.000463	CcSEcCtD
Aprepitant—Nausea—Abacavir—acquired immunodeficiency syndrome	3.85e-05	0.000461	CcSEcCtD
Aprepitant—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	3.84e-05	0.00046	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	3.84e-05	0.00046	CcSEcCtD
Aprepitant—Fatigue—Ritonavir—acquired immunodeficiency syndrome	3.83e-05	0.000459	CcSEcCtD
Aprepitant—Urticaria—Delavirdine—acquired immunodeficiency syndrome	3.82e-05	0.000458	CcSEcCtD
Aprepitant—Asthenia—Indinavir—acquired immunodeficiency syndrome	3.82e-05	0.000457	CcSEcCtD
Aprepitant—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	3.82e-05	0.000457	CcSEcCtD
Aprepitant—Hypotension—Lamivudine—acquired immunodeficiency syndrome	3.81e-05	0.000457	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.81e-05	0.00183	CbGpPWpGaD
Aprepitant—Somnolence—Saquinavir—acquired immunodeficiency syndrome	3.8e-05	0.000456	CcSEcCtD
Aprepitant—Pain—Ritonavir—acquired immunodeficiency syndrome	3.8e-05	0.000456	CcSEcCtD
Aprepitant—Constipation—Ritonavir—acquired immunodeficiency syndrome	3.8e-05	0.000456	CcSEcCtD
Aprepitant—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	3.8e-05	0.000455	CcSEcCtD
Aprepitant—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	3.8e-05	0.000455	CcSEcCtD
Aprepitant—Dizziness—Zidovudine—acquired immunodeficiency syndrome	3.78e-05	0.000453	CcSEcCtD
Aprepitant—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	3.77e-05	0.000451	CcSEcCtD
Aprepitant—Pruritus—Indinavir—acquired immunodeficiency syndrome	3.76e-05	0.000451	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.74e-05	0.0018	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.74e-05	0.0018	CbGpPWpGaD
Aprepitant—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	3.72e-05	0.000446	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	3.72e-05	0.000446	CcSEcCtD
Aprepitant—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	3.7e-05	0.000444	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	3.69e-05	0.000443	CcSEcCtD
Aprepitant—Insomnia—Lamivudine—acquired immunodeficiency syndrome	3.69e-05	0.000442	CcSEcCtD
Aprepitant—Fatigue—Saquinavir—acquired immunodeficiency syndrome	3.69e-05	0.000442	CcSEcCtD
Aprepitant—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	3.67e-05	0.000439	CcSEcCtD
Aprepitant—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	3.66e-05	0.000439	CcSEcCtD
Aprepitant—Constipation—Saquinavir—acquired immunodeficiency syndrome	3.66e-05	0.000438	CcSEcCtD
Aprepitant—Pain—Saquinavir—acquired immunodeficiency syndrome	3.66e-05	0.000438	CcSEcCtD
Aprepitant—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	3.64e-05	0.000436	CcSEcCtD
Aprepitant—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	3.64e-05	0.000436	CcSEcCtD
Aprepitant—Vomiting—Zidovudine—acquired immunodeficiency syndrome	3.64e-05	0.000436	CcSEcCtD
Aprepitant—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	3.64e-05	0.000436	CcSEcCtD
Aprepitant—Somnolence—Lamivudine—acquired immunodeficiency syndrome	3.63e-05	0.000435	CcSEcCtD
Aprepitant—Rash—Zidovudine—acquired immunodeficiency syndrome	3.61e-05	0.000432	CcSEcCtD
Aprepitant—Asthenia—Efavirenz—acquired immunodeficiency syndrome	3.61e-05	0.000432	CcSEcCtD
Aprepitant—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	3.6e-05	0.000432	CcSEcCtD
Aprepitant—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	3.59e-05	0.000431	CcSEcCtD
Aprepitant—Headache—Zidovudine—acquired immunodeficiency syndrome	3.58e-05	0.000429	CcSEcCtD
Aprepitant—Pruritus—Efavirenz—acquired immunodeficiency syndrome	3.56e-05	0.000426	CcSEcCtD
Aprepitant—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	3.55e-05	0.000425	CcSEcCtD
Aprepitant—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	3.54e-05	0.000424	CcSEcCtD
Aprepitant—Urticaria—Ritonavir—acquired immunodeficiency syndrome	3.53e-05	0.000423	CcSEcCtD
Aprepitant—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	3.53e-05	0.000423	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	3.52e-05	0.000422	CcSEcCtD
Aprepitant—Fatigue—Lamivudine—acquired immunodeficiency syndrome	3.52e-05	0.000422	CcSEcCtD
Aprepitant—Dizziness—Indinavir—acquired immunodeficiency syndrome	3.52e-05	0.000421	CcSEcCtD
Aprepitant—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	3.51e-05	0.000421	CcSEcCtD
Aprepitant—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	3.51e-05	0.000421	CcSEcCtD
Aprepitant—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	3.5e-05	0.000419	CcSEcCtD
Aprepitant—Pain—Lamivudine—acquired immunodeficiency syndrome	3.49e-05	0.000418	CcSEcCtD
Aprepitant—Constipation—Lamivudine—acquired immunodeficiency syndrome	3.49e-05	0.000418	CcSEcCtD
Aprepitant—Asthenia—Delavirdine—acquired immunodeficiency syndrome	3.45e-05	0.000413	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.45e-05	0.00165	CbGpPWpGaD
Aprepitant—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	3.44e-05	0.000412	CcSEcCtD
Aprepitant—Pruritus—Delavirdine—acquired immunodeficiency syndrome	3.4e-05	0.000408	CcSEcCtD
Aprepitant—Urticaria—Saquinavir—acquired immunodeficiency syndrome	3.4e-05	0.000407	CcSEcCtD
Aprepitant—Nausea—Zidovudine—acquired immunodeficiency syndrome	3.4e-05	0.000407	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.39e-05	0.00163	CbGpPWpGaD
Aprepitant—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	3.38e-05	0.000405	CcSEcCtD
Aprepitant—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	3.38e-05	0.000405	CcSEcCtD
Aprepitant—Vomiting—Indinavir—acquired immunodeficiency syndrome	3.38e-05	0.000405	CcSEcCtD
Aprepitant—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	3.36e-05	0.000403	CcSEcCtD
Aprepitant—Rash—Indinavir—acquired immunodeficiency syndrome	3.35e-05	0.000402	CcSEcCtD
Aprepitant—Dermatitis—Indinavir—acquired immunodeficiency syndrome	3.35e-05	0.000401	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.34e-05	0.0016	CbGpPWpGaD
Aprepitant—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	3.34e-05	0.0004	CcSEcCtD
Aprepitant—Headache—Indinavir—acquired immunodeficiency syndrome	3.33e-05	0.000399	CcSEcCtD
Aprepitant—Dizziness—Efavirenz—acquired immunodeficiency syndrome	3.32e-05	0.000398	CcSEcCtD
Aprepitant—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	3.29e-05	0.000394	CcSEcCtD
Aprepitant—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	3.28e-05	0.000392	CcSEcCtD
Aprepitant—Urticaria—Lamivudine—acquired immunodeficiency syndrome	3.24e-05	0.000389	CcSEcCtD
Aprepitant—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	3.23e-05	0.000387	CcSEcCtD
Aprepitant—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	3.23e-05	0.000387	CcSEcCtD
Aprepitant—Vomiting—Efavirenz—acquired immunodeficiency syndrome	3.2e-05	0.000383	CcSEcCtD
Aprepitant—Asthenia—Ritonavir—acquired immunodeficiency syndrome	3.19e-05	0.000382	CcSEcCtD
Aprepitant—Dizziness—Delavirdine—acquired immunodeficiency syndrome	3.18e-05	0.000381	CcSEcCtD
Aprepitant—Rash—Efavirenz—acquired immunodeficiency syndrome	3.17e-05	0.00038	CcSEcCtD
Aprepitant—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	3.17e-05	0.000379	CcSEcCtD
Aprepitant—Nausea—Indinavir—acquired immunodeficiency syndrome	3.16e-05	0.000379	CcSEcCtD
Aprepitant—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	3.15e-05	0.000378	CcSEcCtD
Aprepitant—Headache—Efavirenz—acquired immunodeficiency syndrome	3.15e-05	0.000377	CcSEcCtD
Aprepitant—Pruritus—Ritonavir—acquired immunodeficiency syndrome	3.15e-05	0.000377	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.14e-05	0.00151	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.1e-05	0.00149	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	3.1e-05	0.00149	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.09e-05	0.00148	CbGpPWpGaD
Aprepitant—Asthenia—Saquinavir—acquired immunodeficiency syndrome	3.07e-05	0.000368	CcSEcCtD
Aprepitant—Vomiting—Delavirdine—acquired immunodeficiency syndrome	3.06e-05	0.000366	CcSEcCtD
Aprepitant—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	3.04e-05	0.000364	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.04e-05	0.00146	CbGpPWpGaD
Aprepitant—Rash—Delavirdine—acquired immunodeficiency syndrome	3.03e-05	0.000363	CcSEcCtD
Aprepitant—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	3.03e-05	0.000363	CcSEcCtD
Aprepitant—Pruritus—Saquinavir—acquired immunodeficiency syndrome	3.03e-05	0.000363	CcSEcCtD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.01e-05	0.00145	CbGpPWpGaD
Aprepitant—Headache—Delavirdine—acquired immunodeficiency syndrome	3.01e-05	0.000361	CcSEcCtD
Aprepitant—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	3.01e-05	0.00036	CcSEcCtD
Aprepitant—Nausea—Efavirenz—acquired immunodeficiency syndrome	2.98e-05	0.000358	CcSEcCtD
Aprepitant—Dizziness—Ritonavir—acquired immunodeficiency syndrome	2.94e-05	0.000352	CcSEcCtD
Aprepitant—Asthenia—Lamivudine—acquired immunodeficiency syndrome	2.93e-05	0.000351	CcSEcCtD
Aprepitant—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	2.93e-05	0.000351	CcSEcCtD
Aprepitant—Pruritus—Lamivudine—acquired immunodeficiency syndrome	2.89e-05	0.000346	CcSEcCtD
Aprepitant—Nausea—Delavirdine—acquired immunodeficiency syndrome	2.86e-05	0.000342	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.85e-05	0.00137	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.84e-05	0.00136	CbGpPWpGaD
Aprepitant—Dizziness—Saquinavir—acquired immunodeficiency syndrome	2.83e-05	0.000339	CcSEcCtD
Aprepitant—Vomiting—Ritonavir—acquired immunodeficiency syndrome	2.83e-05	0.000339	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.83e-05	0.00136	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.81e-05	0.00135	CbGpPWpGaD
Aprepitant—Rash—Ritonavir—acquired immunodeficiency syndrome	2.8e-05	0.000336	CcSEcCtD
Aprepitant—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	2.8e-05	0.000336	CcSEcCtD
Aprepitant—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	2.79e-05	0.000335	CcSEcCtD
Aprepitant—Headache—Ritonavir—acquired immunodeficiency syndrome	2.79e-05	0.000334	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	2.75e-05	0.00132	CbGpPWpGaD
Aprepitant—Vomiting—Saquinavir—acquired immunodeficiency syndrome	2.72e-05	0.000326	CcSEcCtD
Aprepitant—Dizziness—Lamivudine—acquired immunodeficiency syndrome	2.7e-05	0.000323	CcSEcCtD
Aprepitant—Rash—Saquinavir—acquired immunodeficiency syndrome	2.7e-05	0.000323	CcSEcCtD
Aprepitant—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	2.7e-05	0.000323	CcSEcCtD
Aprepitant—Headache—Saquinavir—acquired immunodeficiency syndrome	2.68e-05	0.000321	CcSEcCtD
Aprepitant—CYP3A7—Metabolism—TAT—acquired immunodeficiency syndrome	2.66e-05	0.00128	CbGpPWpGaD
Aprepitant—Nausea—Ritonavir—acquired immunodeficiency syndrome	2.64e-05	0.000316	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.6e-05	0.00125	CbGpPWpGaD
Aprepitant—Vomiting—Lamivudine—acquired immunodeficiency syndrome	2.6e-05	0.000311	CcSEcCtD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.59e-05	0.00124	CbGpPWpGaD
Aprepitant—Rash—Lamivudine—acquired immunodeficiency syndrome	2.57e-05	0.000308	CcSEcCtD
Aprepitant—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	2.57e-05	0.000308	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.57e-05	0.00123	CbGpPWpGaD
Aprepitant—Headache—Lamivudine—acquired immunodeficiency syndrome	2.56e-05	0.000306	CcSEcCtD
Aprepitant—Nausea—Saquinavir—acquired immunodeficiency syndrome	2.54e-05	0.000305	CcSEcCtD
Aprepitant—Nausea—Lamivudine—acquired immunodeficiency syndrome	2.42e-05	0.000291	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.35e-05	0.00113	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AGPS—acquired immunodeficiency syndrome	2.26e-05	0.00109	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.21e-05	0.00106	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.21e-05	0.00106	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.21e-05	0.00106	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	2e-05	0.000962	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	2e-05	0.000962	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	1.92e-05	0.000923	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.79e-05	0.000861	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.78e-05	0.000857	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.68e-05	0.000808	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.66e-05	0.000796	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	1.63e-05	0.000785	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.63e-05	0.000784	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.52e-05	0.000728	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	1.49e-05	0.000713	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.48e-05	0.000712	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	1.36e-05	0.00065	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	1.26e-05	0.000607	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.16e-05	0.000556	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.15e-05	0.000553	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.05e-05	0.000506	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	9.85e-06	0.000473	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	8.94e-06	0.000429	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.76e-06	0.00042	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.72e-06	0.000418	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	7.6e-06	0.000365	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.82e-06	0.000279	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.31e-06	0.000255	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.15e-06	0.000247	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	4.64e-06	0.000223	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.54e-06	0.000218	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	3.35e-06	0.000161	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	2.59e-06	0.000124	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	2.36e-06	0.000113	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	2.02e-06	9.69e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.56e-06	7.48e-05	CbGpPWpGaD
